Valacyclovir Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global valacyclovir market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Valacyclovir is a member of the purine nucleoside analog drug class, used to treat certain infections such as herpes, varicella, and others caused by the virus. The rise in the prevalence of the EB virus is anticipated to drive the global valacyclovir market. EB virus is a double standard DNA virus that infects B lymphocyte cells. It can cause a variety of diseases and is spread mainly from the saliva-containing virus-infected epithelial cells. For instance, according to the data published by National Center for Biotechnology (NCBI) in 2021, approximately 95.0% of the global population of adults had been affected by the EB virus. In the US, the EB virus among children aged 6 to 19 years accounted for a prevalence of 66.5%. Children between the age of 6-8 years had a prevalence of approximately 54.0%, while adolescents aged 18-to 19 years had a prevalence of more than 82.9%. Moreover, as per NCBI, there was a higher prevalence of EB virus infection in children and adults who had large households, lower household income, and lower parental education.

Moreover, the rise in the incidence of herpes zoster virus is anticipated to drive the growth of the global valacyclovir market. It is a viral disease caused by the reactivation of the varicella-zoster virus which remains dormant in the sensory ganglia of the cranial nerve. For instance, according to the data published by NCBI in 2021, the incidence of herpes zoster is anticipated to range from 1.2 to 3.4 per 1,000 persons annually among younger healthy individuals, while the incidence is 3.9 to 11.8 per 1,000 persons among patients older than 65 years. Moreover, the infection is contagious to individuals who do not possess prior immunity to varicella-zoster. Thus, the rise in the incidence of herpes zoster is anticipated to drive the demand for the global valacyclovir market.

Looking toward the demand for valacyclovir, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in 2021, the National Institute of Health started a phase 2, 52 week trial of oral valacyclovir 4g/day in 50 HSV seropositive, AD biomarker positive, amnestic mild cognitive impairment (MCI) patients. The trial will address the long-standing viral etiology hypothesis of Alzheimer’s disease (AD). Thus, such clinical trials are anticipated to drive the growth of the global valacyclovir market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- GlaxoSmithKline Plc, Jamp Pharmaceutical Corp, and Aurobindo Pharmaceutical among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Valacyclovir Market Report by Segment

By Type

• Tablet
• Capsules
• Granules

By Application

• Herpes Zoster Virus
• Herpes Simplex Virus
• EB Virus
• Cytomegalovirus